Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9341849 | 0.82 | CHRNB2 (0.47) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL9967696 | 0.81 | CYP11B1 (0.59) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL6450487 | 0.81 | CYP11B1 (0.59) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL27746559 | 0.81 | CYP11B2 (0.53) | ALDH1A1CYP11B2CYP11B1KMT2AMEN1 | |
| SCHEMBL27888079 | 0.77 | CYP11B2 (0.48) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL213871 | 0.76 | — | — | |
| SCHEMBL14198047 | 0.76 | MAPT (0.58) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL29691639 | 0.75 | CYP11B1 (0.86) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL29691623 | 0.75 | CYP11B1 (0.86) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A | |
| SCHEMBL8911420 | 0.75 | ALDH1A1 (0.62) | ALDH1A1CYP11B2CYP11B1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906069-B1 | Diagnosis indicator; anticholesterol agents; antilipemic agents; antidiabtic agents | AMGEN INC. (US) | 2005-06-14 | — | — | US | claimed |
| US-6906069-B1 | Diagnosis indicator; anticholesterol agents; antilipemic agents; antidiabtic agents | AMGEN INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040152132-A1 | Solid phase synthesis of LXR ligands | TULARIK INC. | 2004-08-05 | — | — | US | disclosed |
| US-6673543-B2 | JOINING LIVER RECEPTORS TO SOLID SUPPORT; GENERATE SOLID SUPPORT, JOIN ANILINE DERIVATIVE TO SUPPORT, INCUBATE WITH ALDEHYE, KETONE, INCUBATE ANILINE DERIVATIVE WITH ACYLATING AGENT, RECOVER SUPPORT | TULARIK, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020072073-A1 | Solid phase synthesis of LXR ligands | AMGEN INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2001077067-A2 | SOLID PHASE SYNTHESIS OF LXR LIGANDS | TULARIK INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001060818-A1 | LXR MODULATORS | TULARIK INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| US-5935954-A | TREATING THE PATIENT SUFFERING FROM PARKINSON'S DISEASE, ALZHIMER'S DISEASE, STROKE AND ISCHEMIA ASSOCIATED WITH STROKE, NEURAL PAROPATHY, SCIATIC CRUSH, SPINAL CORD INJURY OR FACIAL NERVE CRASH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-08-10 | — | — | US | disclosed |
| US-5922725-A | Benzimidazole compounds and their use as modulators of the GABAA receptor complex | NEUROSEARCH A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| US-5717092-A | Compounds with improved multi-drug resistance activity | VERTEX PHARMACEUTICALS INC. (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152132-A1 | Solid phase synthesis of LXR ligands | NR1H2, NR1H3, NR1H4 | ALDH1A1 4003/4885CYP11B2 90/4885CYP11B1 65/4885 |
| US-20020072073-A1 | Solid phase synthesis of LXR ligands | NR1H2, NR1H3, NR1H4 | ALDH1A1 4003/4885CYP11B2 90/4885CYP11B1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.